NMRA Neumora Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1885522 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY19.4%
TTM EPS YoY27.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-252.7%
ROA-139.6%
ROIC (approx.)-332.4%
Asset turnover—
Leverage & solvency
Liabilities / assets80.5%
Debt / equity6.11x
Current ratio4.08x
Interest coverage-34.16x
Cash quality & payout
Operating cash flow / net income0.88x
Accruals ratio-16.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $22.61M | $29.28M | $38.60M | $44.67M | $40.52M | $38.72M | $52.15M | $45.91M |
| SG&A expense | $10.79M | $12.91M | $14.27M | $13.81M | $12.18M | $15.32M | $18.79M | $17.01M |
| Operating income | -$33.41M | -$42.19M | -$52.86M | -$58.48M | -$57.70M | -$54.04M | -$70.94M | -$62.92M |
| Interest expense | $1.44M | $1.43M | $1.44M | $1.17M | $534,000 | $307,000 | $0 | $0 |
| Pretax income | -$34.44M | -$43.08M | -$53.43M | -$59.45M | -$56.76M | -$52.71M | -$67.89M | -$58.82M |
| Income tax | $0 | $0 | $30,000 | $0 | $0 | $25,000 | $105,000 | $0 |
| Net income | -$34.44M | -$43.08M | -$53.46M | -$59.45M | -$56.76M | -$52.73M | -$67.99M | -$58.82M |
| EBITDA | -$33.41M | -$42.18M | -$52.86M | -$58.47M | -$57.68M | -$54.02M | -$70.78M | -$62.77M |
| EPS (basic) | -0.18 | -0.23 | -0.30 | — | -0.35 | -0.33 | -0.42 | — |
| EPS (diluted) | -0.18 | -0.23 | -0.30 | — | -0.35 | -0.33 | -0.42 | — |
| Weighted avg. shares (diluted) | 187.90M | 185.16M | 179.87M | — | 161.84M | 161.69M | 161.45M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $85.65M | $116.83M | $147.07M | $182.53M | $129.07M | $124.52M | $126.86M | $142.15M |
| Short-term investments | — | — | — | — | $42.45M | $93.06M | $122.49M | $165.43M |
| Current assets | $94.75M | $124.87M | $153.43M | $190.54M | $177.08M | $222.91M | $254.87M | $314.06M |
| PP&E, net | — | $25,000 | $32,000 | $40,000 | $80,000 | $87,000 | $982,000 | $1.14M |
| Total assets | $95.05M | $125.25M | $153.88M | $191.05M | $177.83M | $223.82M | $256.75M | $316.97M |
| Current liabilities | $23.19M | $27.78M | $30.11M | $32.45M | $25.84M | $21.16M | $28.38M | $29.89M |
| Short-term debt | $60.00M | $60.00M | $60.00M | $60.00M | $20.00M | $20.00M | — | — |
| Long-term debt | $53.30M | $52.91M | $52.96M | $54.53M | $19.56M | $19.45M | — | $0 |
| Total debt | $113.30M | $112.91M | $112.96M | $114.53M | $39.56M | $39.45M | — | $0 |
| Total liabilities | $76.50M | $80.73M | $83.20M | $87.18M | $45.67M | $40.95M | $28.38M | $29.91M |
| Shareholders' equity | $18.55M | $44.52M | $70.68M | $103.87M | $132.16M | $182.88M | $228.36M | $287.06M |
| Net debt | $27.65M | -$3.92M | -$34.11M | -$68.00M | -$89.51M | -$85.07M | — | -$142.15M |
| Shares outstanding | — | — | — | 174.26M | — | — | — | 161.71M |
| Cash flow statement | ||||||||
| Operating cash flow | -$33.44M | -$39.53M | -$46.40M | -$47.95M | -$46.63M | -$52.40M | -$59.45M | -$50.34M |
| Investing cash flow | -$71,000 | $0 | $71,000 | $42.65M | $51.32M | $30.40M | $44.16M | -$98.80M |
| Financing cash flow | $2.33M | $9.29M | $10.88M | $58.77M | -$136,000 | $18.46M | $0 | $15.57M |
| Depreciation & amortization | $3,000 | $7,000 | $8,000 | $9,000 | $23,000 | $19,000 | $157,000 | $157,000 |
| Stock-based compensation | $6.14M | $7.18M | $7.41M | $7.41M | $5.98M | $7.17M | $9.32M | $9.90M |
Free plan shows the latest 8 periods; Pro shows all 19 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.